|CDC Publishes Updated Guidance on the Use of Zoster Vaccines|
|Published February 2018|
|A new vaccine for the prevention of herpes zoster was licensed by the Food and Drug Administration in October 2017. Recombinant zoster vaccine (RZV, Shingrix®; GSK) is a subunit vaccine that contains recombinant varicella zoster virus glycoprotein E in combination with a novel adjuvant (AS01B). Shingrix does not contain live varicella zoster virus. It is approved for people 50 years and older and administered as a two-dose series with doses separated by two to six months.
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines was published on Jan. 26, and is available on the MMWR website. The major recommendations contained in this guidance are:
Storage and administration
There are several important differences between Shingrix and Zostavax that staff must understand to avoid storage and administration errors.